HC Wainwright Reaffirms “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 120.02% from the company’s current price.

A number of other brokerages have also commented on TLX. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Citigroup increased their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Trading Down 0.4%

Shares of TLX stock opened at $9.09 on Tuesday. The stock has a fifty day moving average of $7.73 and a 200 day moving average of $8.72. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $20.00. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million during the quarter, compared to the consensus estimate of $421.50 million. As a group, research analysts predict that Telix Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several large investors have recently modified their holdings of TLX. Rhumbline Advisers raised its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals in the 4th quarter worth about $89,000. OLD Mission Capital LLC purchased a new position in shares of Telix Pharmaceuticals in the 4th quarter worth about $111,000. Vident Advisory LLC purchased a new position in shares of Telix Pharmaceuticals in the 4th quarter worth about $204,000. Finally, IHT Wealth Management LLC purchased a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth about $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.